One of the next big goals for the treatment of multiple sclerosis (MS) is the development of therapies that induce or promote remyelination—repairing the damage to the central nervous system done by the disease.

Ari Green, MD, MCR, the medical director of the UCSF Multiple Sclerosis Center and director of the UCSF Neurodiagnostics Center, works closely with colleagues on this exact goal. His belief is not only that this method could work, but based on on his experience, he believes certain approaches may work better than others.

At the the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting in Berlin, Germany, Green sat with NeurologyLive to discuss the idea behind remyelination, and to share his thoughts on what the best shot at developing a therapy might be.

свернуть